RT Journal Article SR Electronic T1 Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.17.20134007 DO 10.1101/2020.06.17.20134007 A1 Mariam Ayed A1 Abdulwahab A Borahmah A1 Anwar Yazdani A1 Ahmad Sultan A1 Ahmad Mossad A1 Hanouf Rawdhan YR 2020 UL http://medrxiv.org/content/early/2020/06/22/2020.06.17.20134007.abstract AB Purpose To assess the clinical characteristics and identify mortality predicting factors in intensive care unit (ICU)-admitted COVID-19 confirmed patients.Methods We recruited and analyzed COVID-19 infected adult patients (ageā‰„ 18 years) who were admitted to the ICU at Jaber AlAhmad Al Sabah Hospital,Kuwait, between 1stMarch, 2020and 30thApril 2020. The patients were followed up to 20th May, 2020. The risk factors associated with in-hospital mortality were assessed using multiple regression analysis.Results We recruited a total of 103 ICU patients in this retrospective cohort. The median age of the patients was 53 years (Interquartile Range (IQR): 44-63 years). The fatality rate was 43.7%. Among the patients, majority were males (85.5%) and 38% patients had more than two comorbidities. Pre-existing hypertension (OR:3.2,95%CI: 1.2-8.9), moderate/severe ARDS (OR: 3.4, 95%CI: 1.1-10.8),lymphocyte counts <0.5 (OR: 6.1, 95%CI: 1.2-29.8)albumin < 22 (OR: 7.5, 95%CI: 2.1-26.2), procalcitonin >0.2 (OR: 3.8, 95%CI: 1.3-7.8), D-Dimer >1200 (OR: 5.1, 95%CI: 1.2-21.6), and the need forcontinuous renal replacement therapy (OR: 9.3, 95%CI: 2.4-36.2) weresignificantly associated with mortality.Conclusion This study describes the clinical characteristics and predictors ofmortality among ICU patients. Early identification of risk factors to mortality might help in their better outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB 2020/1411All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available(ICU)Intensive care unit(RT-PCR)Real-time reversetranscriptasepolymerasechainreaction(RRT)Renal replacement therapy(ECMO)Extracorporeal membrane oxygenation(ARDS)Acute respiratory distress syndrome(qSOFA)Quick Sequential Failure Assessment(ACEI)Angiotensin converting enzyme inhibitors(PCT)Procalcitonin(CRP)C-reactive protein